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26.1 ± 5.3; group 2, 27.9 ± 5.2; group 3, 24.3 ± 4.2; group 4, 
27.9 ± 7.5; group 5, 24.7 ± 5.2 (p > 0.05). There were no dif-
ferences in the lipid profile, plasma glucose, HOMA-IR, insu-
lin and M values between the groups (p > 0.05). Phenotypes 
with oligomenorrhea/anovulation (groups 1, 2 and 4) were 
more obese than group 3 (p = 0.039).  Conclusions: The car-
diometabolic risk profile was similar among the PCOS sub-
groups. This finding could be attributed to the mean BMl 
values, which, being below 30, were not within the obesity 
range. Obesity appeared to be an important determinant of 
high cardiovascular risk in PCOS.  © 2015 S. Karger AG, Basel 
 Introduction 
 Polycystic ovary syndrome (PCOS) is a complex dis-
order characterized by a cluster of major cardiovascular 
(CV) risk factors. Insulin resistance (IR) is regarded as a 
key feature of PCOS. The association between IR and glu-
cose metabolic disorders, such as impaired glucose toler-
ance, type 2 diabetes and CV disease, has been reported 
 [1, 2] . The findings indicated that women with PCOS and 
IR are at high risk of metabolic disorders. Of equal impor-
tance, Boudreaux et al.  [3] reported a 5-fold increased risk 
of type 2 diabetes among women with PCOS after 8 years 
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 Abstract 
 Objective: The aim of this study was to determine the car-
diometabolic risk factors in different polycystic ovary syn-
drome (PCOS) phenotypes.  Subjects and Methods: This 
cross-sectional study was performed between 2010 and 
2011. Eighty-nine patients with PCOS and 25 age- and 
weight-matched healthy controls were included in the 
study. Patients were grouped using the Rotterdam 2003 cri-
teria as: group 1, oligomenorrhea and/or anovulation (ANOV) 
and hyperandrogenemia (HA) and/or hyperandrogenism
(n = 23); group 2, ANOV and polycystic ovaries (PCO; n = 22); 
group 3, HA and PCO (n = 22); group 4, ANOV, HA and PCO 
(n = 22); group 5, controls (n = 25). Laboratory blood tests for 
diagnosis and cardiometabolic risk assessments were per-
formed. Insulin resistance (IR) was calculated in all patients 
with the homeostasis model assessment of IR (HOMA-IR) for-
mula. An euglycemic hyperinsulinemic clamp test was per-
formed on 5 randomly selected cases in each subgroup, 
making 25 cases in total, and indicated as the ‘M’ value
(mg/kg/min), which is the total body glucose disposal rate. 
 Results: The mean BMl values of the groups were: group 1, 
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of follow-up  [3] . Although there are conflicting reports, 
the risk of diabetes is claimed to occur independently of 
obesity, and may be worsened by obesity  [3–5] . It has 
been observed that abdominal obesity and PCOS interact 
to promote premature atherosclerosis and increase CV 
mortality  [6] .
 In 1992, the National Institutes of Health (NIH) pro-
posed a diagnostic criteria  [7] concentrating primarily on 
hyperandrogenism and anovulation for PCOS. After ex-
cluding all other etiological causes, the NIH criteria re-
quired the presence of oligo-/anovulation and hyperan-
drogenemia/hyperandrogenism. In 2003, in Rotterdam, 
the European Society for Human Reproduction and Em-
bryology/American Society for Reproductive Medicine 
(ESHRE/ASRM) formulated a new set of criteria which 
added two new phenotypes – hyperandrogenic ovulatory 
and nonhyperandrogenic anovulatory women – to the 
spectrum of the syndrome  [8] . The Rotterdam 2003 cri-
teria are now used worldwide for the diagnosis of PCOS; 
however, it has not been clarified whether or not various 
PCOS phenotypes carry different CV risk profiles.
 Although patients with full-blown PCOS are supposed 
to carry the worst CV risk profile, studies comparing dif-
ferent phenotypes demonstrate various results  [9–12] . 
Body mass index (BMI) and plasma insulin have been 
reported to be higher in PCOS patients with oligo-/
amenorrhea and hyperandrogenemia/hyperandrogen-
ism compared to the ones with hyperandrogenemia/
hyperandrogenism and polycystic ovaries (PCO)  [10–
12] . Irregular menstrual cycles have been associated with 
an increased risk for CV mortality  [13] . Also, amenorrhea 
has been demonstrated to accompany a more pronounced 
IR than oligomenorrhea and polymenorrhea  [14] . In the 
present study, we investigated whether or not traditional 
CV risk profiles differed among various nonobese PCOS 
patients diagnosed according to Rotterdam 2003 criteria.
 Subjects and Methods 
 This cross-sectional study was performed at the outpatient
endocrinology clinic of Baskent University Faculty of Medicine, 
Adana Hospital, and eligible patients were recruited between Feb-
ruary 2010 and June 2011. Eighty-nine newly diagnosed PCOS pa-
tients and 25 age- and weight-matched healthy controls were 
included in the study. The exclusion criteria were current smoking, 
chronic heavy alcohol consumption, severe obesity (BMI >35), ac-
companying chronic kidney or liver disease or malignancy, any 
chronic metabolic disease such as diabetes and hypertension, etc., 
and any chronic medication use.
 The diagnosis of PCOS was performed according to the Rot-
terdam 2003 criteria  [8] requiring copresentation of at least two of 
oligomenorrhea and/or anovulation (ANOV), hyperandrogen-
emia and/or hyperandrogenism (HA), and/or PCO at ultrasono-
graphic examination. The 89 patients were divided into the follow-
ing subgroups: group 1, ANOV and HA (n = 23); group 2, ANOV 
and PCO (n = 22); group 3, HA and PCO (n = 22); group 4, ANOV, 
HA and PCO (n = 22); group 5, healthy controls (n = 25). Cases 
admitted with the complaint of hirsutism but who after diagnostic 
work-up did not provide sufficient criteria for PCOS were includ-
ed in the control group; all had ovulatory cycles.
 Euglycemic hyperinsulinemic clamp (EHC) was performed on 
25 randomly selected cases and the results were recorded as the M 
value (mg/kg/min)  [15] . The total number of the participants in 
the subgroups and the number of cases subjected to EHC in each 
subgroup, respectively, were: group 1, 23 and 5; group 2, 22 and 4; 
group 3, 22 and 6; group 4, 22 and 5; group 5, 25 and 5.
 The PCOS patients were also separated into two groups regard-
ing their menstrual state – those with ANOV (groups 1, 2 and 4; 
ANOV positive, n = 67) and those without ANOV (group 3; 
ANOV negative, n = 22). The cardiometabolic risks between these 
groups were compared.
 Study Protocol 
 The study protocol was approved by the Institutional Ethics 
Committee. Each participant gave written informed consent, their 
medical history was taken, a physical examination was performed 
and their BMI was calculated as body weight (kg)/height (m) 2 . 
Measurements were made early in the morning following urina-
tion with an empty stomach and with light clothing using the Seca 
model 220 digital device (Seca, Hamburg, Germany). Obesity was 
determined as a BMI threshold of >30  [16] . Hirsutism was defined 
as a modified Ferriman-Gallwey score equal to or higher than 8 
 [17] . Menstruating patients between the 2nd to 5th days of their 
cycle and amenorrheic cases on any day were subjected to hor-
monal analyses for diagnosing PCOS. An oral glucose tolerance 
test (OGTT) with 75 g of glucose after 8–10 h of overnight fasting, 
following at least 3 days of a diet containing 300 g of carbohydrate, 
was performed on all subjects. Blood samples for glucose and in-
sulin were obtained from the forearm vein at 0 min and for glucose 
only at 120 min of the test. The peripheral insulin sensitivity of the 
participants was calculated using the homeostasis model assess-
ment of IR (HOMA-IR) formula: fasting venous glucose (mmol/l) 
× fasting insulin (mU/ml)/22.5  [18] .
 Serum follicle-stimulating hormone, luteinizing hormone 
(LH), estradiol, total testosterone, prolactin, thyroid-stimulating 
hormone and 17-OH progesterone, whole blood count, total cho-
lesterol, high-density lipoprotein cholesterol, low-density lipo-
protein and triglyceride were measured simultaneously in early 
morning fasting serum samples. A randomly selected comparable 
number of participants were subjected to serum fibrinogen mea-
surement (group1, 17; group 2, 17; group 3, 15; group 4, 19; group 
5, 19).
 Glucose and lipid measurements were performed using the col-
orimetric method, 17-OH progesterone levels were measured us-
ing ELISA and all other biochemical parameters were processed 
using the chemiluminescence microparticle immunoassay meth-
od, with a reference limit for total testosterone of 0.14–0.76 ng/ml. 
EHC as defined by DeFronzo et al.  [15] was performed for detect-
ing IR.
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 Statistical Analysis  
 The Statistical Package for the Social Sciences version 18.0 
(SSPS Inc., Chicago, Ill., USA) was used for the statistical analyses. 
Categorical data were expressed as number and percentages, nu-
meric data were expressed as the mean and standard deviation 
(SD) or as the median with the minimum and maximum range. 
Standard descriptive analysis, χ 2 test, independent samples t test 
and the Mann-Whitney U test were used where appropriate. Gen-
eralized linear models were used for the comparison of the study 
and control groups. A p value <0.05 was considered as statistically 
significant.
 Results 
 There was no statistically significant difference among 
the groups regarding mean age (p = 0.081) and BMI val-
ues (group 1, 26.1 ± 5.3; group 2, 27.9 ± 5.2; group 3, 24.3 
± 4.2; group 4, 27.9 ± 7.5; group 5, 24.7 ± 5.2; p = 0.09). 
Hormonal analyses did not reveal significant differences 
among the groups, excluding total testosterone and LH. 
Groups 1, 3 and 4 had higher total testosterone than 
group 5, whereas groups 2 and 4 had higher LH than 
group 5 (p = 0.000 and 0.024, respectively;  table 1 ). The 
PCOS group had statistically higher LH, total testoster-
one, post-OGTT 2nd hour plasma glucose (pOGTT),
fibrinogen and triglyceride levels than the control group
(p = 0.013, 0.004, 0.013, 0.025 and 0.045, respectively;  ta-
ble 2 ).
 Analyses of cardiometabolic risk factors, including
lipid profile, fasting plasma glucose, pOGTT, insulin, 
HOMA-IR and M values, revealed no statistically signifi-
cant difference among the groups (p > 0.05), as shown in 
 table 3 . Regarding the ovulatory status of the patients, the 
ANOV-positive cases had a higher BMI (27.3 vs. 24.3,
p = 0.039). However, their cardiometabolic risk factors 
exhibited a similar profile (p > 0.05).
 Cardiometabolic risk factors were similar between the 
classical PCOS patients diagnosed according to the NIH 
1990 criteria (groups 1 and 4) and the new phenotypes 
defined by the Rotterdam 2003 criteria (groups 2 and 3,
p > 0.05;  table 4 ).
 Discussion 
 This cross-sectional study, which used the Rotterdam 
2003 criteria in age- and weight-matched groups of PCOS 
phenotypes with mean BMIs below the obesity cutoff 
(BMI >30), demonstrated that nonobese phenotypes ex-
hibited similar CV risk profiles. The M values obtained 
by EHC, which is the gold standard method for evaluating 
IR, were in accordance with the other cardiometabolic 
risk factors we studied.
 Table 1.  Details of demographic features and hormonal findings of the participants performed for diagnosing PCOS
Group 1:
ANOV and HA
(n = 23)
Group 2: 
ANOV and PCO 
(n = 22)
Group 3: 
HA and PCO 
(n = 22)
Group 4:
ANOV, HA and PCO
(n = 22)
Group 5:
control 
(n = 25)
p
Age, years 24.2 ± 5.9 23.4± 5.7 23.18 ± 3.92 22.7 ± 4.8 24.2 ± 5.0 0.81
BMI 26.1 ± 5.3 27.9 ± 5.2 24.3 ± 4.2 27.9 ± 7.5 24.7 ± 5.2 0.09
FSH, mIU/ml 4.3 ± 1.4 4.1 ± 1.6 4.4 ± 0.8 4.7 ± 1.2 4.9 ± 1.4 0.22
LH, mIU/ml 5.0 (0.45 – 6.9) 5.7 (0.45 – 11.57) 4.6 (2.7 – 14.8) 6.4 (1.8 – 16.1) 3.4 (1.5 – 6.3) 0.024
E2, pg/ml 34.9 (10 – 68) 40.4 (10 – 82) 40.2 (19 – 76) 45.0 (14 – 84) 37.1 (16 – 74) 0.24
Total testosterone, ng/ml 1.06 ± 0.4 0.8 ± 0.1 1.1 ± 0.3 1.0 ± 0.3 0.7 ± 0.2 0.000
Prolactin, mIU/l 505 (145 – 2,903) 394.3 (117 – 888) 436.3 (142 – 1,020) 382.9 (164.6 – 1,166) 433.3 (100 – 747) 0.67
 FSH = Follicle-stimulating hormone; E2 = estradiol.
 Table 2.  List of parameters exhibiting a statistically significant dif-
ference between the study and control groups
PCOS 
(n = 89)
Control 
(n = 25)
p
LH, mIU/ml 5.4 (0.5 – 16.6) 3.4 (1.5 – 6.3) 0.013
Total testosterone, ng/ml 1.0 ± 0.3 0.7 ± 0.2 0.004
pOGTT, mg/dl 106.5 ± 22.4 94.1 ± 18.3 0.013
Fibrinogen, g/l 3.3 ± 0.6 3.0 ±0.5 0.025
Triglyceride, mg/dl 102.7 (30 – 363) 87.4 (29 – 305) 0.045
 Values are the mean ± SD or median (minimum–maximum).
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 The association between PCOS and CV risk factors has 
been identified in the literature  [19–21] . Svendsen et al. 
 [22] demonstrated that PCOS patients have higher 2nd 
hour glucose levels during an OGTT test than their non-
PCOS peers. In a meta-analysis including 35 PCOS stud-
ies that investigated the syndrome’s association with met-
abolic disorders (impaired glucose tolerance, type 2 dia-
betes and metabolic syndrome) PCOS cases were found 
to carry worse CV risk profiles  [23] . Accordingly, our 
PCOS cases exhibited higher 2nd hour plasma glucose, 
fibrinogen and triglyceride levels. The differences regard-
ing total testosterone and LH values among our groups 
were considered to result from the diagnostic criteria. 
 Studies analyzing the CV risk profiles of various PCOS 
phenotypes have focused on the negative impact of obe-
sity and IR  [9, 23, 24] . As is the case in type 2 diabetes, 
excessive adipose tissue is considered to play a crucial role 
in the development of PCOS. However, not all obese 
women, but rather those that are genetically vulnerable, 
progress to the syndrome. Obesity is claimed to cause 
more severe PCOS phenotypes from both a metabolic 
and reproductive point of view  [25] . In a study by Ketel 
et al.  [26] , PCOS patients with central obesity demon-
strated an increased arterial stiffness than their nonobese 
peers. Additionally, EHC was performed and lower M 
values were found in the obese PCOS cases included in 
that study. The authors concluded that insulin sensitivity 
decreases in parallel to increasing central adipose tissue 
in PCOS. In our study, the M values of the groups were 
not different and the mean BMl values were not within 
the obesity range. Our findings also pointed to the critical 
role of obesity in the development of the high CV risk 
profile of the syndrome.
 In a previous study, Rizzo et al.  [27] found that women 
with ovulatory PCOS have milder forms of atherogenic 
dyslipidemia than anovulatory PCOS. Using the Rotter-
dam 2003 criteria, another study succinctly showed that 
PCOS phenotypes with oligo-/anovulation and hyper-
androgenism have more severe metabolic problems and 
 Table 3.  Comparison of the groups according to cardiometabolic risk factors
Group 1:
ANOV and HA
(n = 23)
Group 2:
ANOV and PCO
(n = 22)
Group 3:
HA and PCO
(n = 22)
Group 4:
ANOV and HA 
and PCO (n = 22)
Group 5:
control
(n = 25)
p
Total cholesterol, mg/dl 170.3 ± 32.7 170.6 ± 30.8 156.1 ± 24.0 170.8 ± 38.2 159.1 ± 33.1 0.34
HDL cholesterol, mg/dl 42.1 ± 10.2 45.2 ± 9.3 44.5 ± 8.3 51 ± 11.5 47.4 ± 15.3 0.10
LDL cholesterol, mg/dl 103.2 ± 27.1 102.3 ± 25.7 91.1 ± 22.2 99.1 ± 31.7 92.2 ± 27.3 0.41
Triglycerides, mg/dl 113.8 (40 – 249) 102.9 (40 – 249) 93.0 (30 – 240) 100.6 (42 – 246) 87.4 (29 – 305) 0.67
Fibrinogen, g/l 3.4 ± 0.5 3.4 ± 0.6 3.4 ± 0.5 3.2 ± 0.8 3.0 ± 0.5 0.19
FPG, mg/dl 86.3 ± 7.02 90.6 ± 8.3 87.0 ± 5.7 90.7 ± 7.6 89.3 ± 8.2 0.16
pOGTT, mg/dl 104.7 ± 25.4 110.7 ± 22.4 104.6 ± 19.2 106.2 ± 23.0 94.1 ± 18.3 0.12
Insulin, μIU/ml 12.2 (3.5 – 46) 13.4 (1.3 – 51) 9.6 (4.5 – 21.1) 12.3 (4.6 – 24.6) 8.7 (3.1 – 15.4) 0.18
HOMA-IR 2.6 (0.7 – 9.6) 3.0 (0.3 – 12.5) 2.0 (0.8 – 4.2) 2.7 (1.4 – 5.8) 1.9 (0.6 – 3.7) 0.14
M, mg/kg/min 4.5 (1.4 – 7.7) 4.8 (3.3 – 6.7) 4.8 (3.5 – 6.4) 3.7 (1.8 – 6.2) 4.9 (2.0 – 6.9) 0.84
 Values are the mean ± SD or the median (minimum–maximum). HDL = High-density lipoprotein; LDL = low-density lipoprotein; 
FPG = fasting plasma glucose.
 Table 4.  Comparison of cardiometabolic risk profiles of classical 
PCOS patients diagnosed according to the NIH 1990 criteria and 
the new phenotypes defined by the Rotterdam 2003 criteria
NIH 1990
(n = 45)
Rotterdam 2003
(n = 44)
p
Total cholesterol, mg/l 170.5 ± 35.13 163.3 ± 28.2 0.29
HDL cholesterol, mg/dl 46.5 ± 11.7 44.8 ± 8.76 0.45
LDL cholesterol, mg/dl 101.2 ± 29.2 96.7 ± 24.4 0.43
Triglycerides, mg/dl 107.4 (42–363) 98 (30 – 249) 0.47
FPG, mg/dl 88.5 ± 7.5 88.8 ± 7.3 0.83
pOGTT, mg/dl 105.4 ± 24.0 107.7 ± 20.8 0.63
Insulin, μIU/ml 12.2 (3.5 – 46.0) 11.5 (1.30 – 51.0) 0.89
HOMA-IR 2.6 (0.7 – 9.6) 2.5 (0.3 – 12.5) 0.83
M, mg/kg/min 4.1 (1.4 – 7.7) 4.8 (3.3 – 6.7) 0.40
 Values are the mean ± SD or the median (minimum–maxi-
mum). NIH 1990 criteria patients: group 1 (ANOV and HA) + 
group 4 (ANOV, HA and PCO); Rotterdam 2003 criteria patients: 
group 2 (ANOV + PCO) + group 3 (HA + PCO). HDL = High-
density lipoprotein; LDL = low-density lipoprotein; FPG = fasting 
plasma glucose.
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higher BMI values  [9] . The positive correlation between 
HOMA-IR and BMI values in that study are considered 
as solid evidence for the worsening of PCOS symptoms 
with increasing fat tissue. Accordingly, the statistically
insignificant difference in insulin sensitivity measures as 
well as other CV risk parameters among our PCOS phe-
notypes can be attributed to the similar mean BMI values, 
which were not within the obesity range.
 The impact of oligo-/anovulation and/or hyperandro-
genemia has been investigated on the CV risk profile of 
PCOS patients before. In some studies, oligo-/anovula-
tion has been claimed to exert a stronger negative impact 
than hyperandrogenemia  [24, 28] . Conversely, Mehrabi-
an et al.  [29] found the incidence of metabolic syndrome 
to be higher in oligo-/anovulatory and hyperandrogen-
emic PCOS cases than oligo-/anovulatory and normoan-
drogenemic subjects using the Rotterdam 2003 criteria. 
They concluded that hyperandrogenemia has the more 
powerful effect. In our study, oligo-/anovulatory PCOS 
cases clearly demonstrated higher BMI values. On the 
other hand, the statistically indifferent CV risk profiles 
between our ovulatory and oligo-/anovulatory groups 
were unexpected. Considering the relatively low mean 
BMI values of our groups, the link between CV risk and 
obesity may be proposed to begin at higher BMI levels, or 
there may be some other, stronger contributing factors.
 Anaforoglu et al.  [30] demonstrated that cases diag-
nosed according to the NIH criteria, usually referred to as 
the classical PCOS patients, have higher HOMA-IR and 
triglyceride levels than patients diagnosed with the Rot-
terdam 2003 criteria. Their findings again underline the 
impact of the amount of fat tissue on the PCOS pheno-
type as their NIH patients were heavier (30.3 ± 8.4 vs.
28.1 ± 6.4), even though this was statistically insignificant 
(p = 0.065). In our study group, we also compared the 
classical PCOS cases with the newly defined phenotypes 
of the Rotterdam 2003 criteria regarding CV risk profiles 
and demonstrated no difference. The similar risk profiles 
of our two groups may again be attributed to their indif-
ferent mean BMI values, which were below the obesity 
threshold.
 The limitations of the present study should be consid-
ered. First is the measurement of serum testosterone levels 
using a nonvalidated method. However, the gold standard 
method (LC-MS/MS) is not readily available in our coun-
try. A second limitation is that we did not measure waist 
circumference for determining central obesity. Instead 
the BMI calculations were performed in order to avoid 
taking the risk of possible millimetric measurement faults 
in our relatively normally weighted PCOS population. 
 Conclusion 
 The similar risk profiles at mean BMI levels below the 
obesity cutoff in this study provide a clue for the possible 
impact of adiposity. From a clinical standpoint, we be-
lieve that overweight and obese PCOS cases require more 
attention.
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